Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

被引：0
|
作者：
Sonneveld, Pieter [1 ]
Asselbergs, Emilie [1 ]
Zweegman, Sonja [2 ]
Van der Holt, Bronno [3 ]
Kersten, Marie Jose [4 ]
Vellenga, Edo [5 ]
van Marwijk-Kooy, Marinus [6 ]
de Weerdt, Okke [7 ]
Lonergan, Sarah
Lokhorst, Henk [8 ]
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands
[3] Erasmus MC, HOVON Data Ctr, Rotterdam, Netherlands
[4] AMC, Amsterdam, Netherlands
[5] Univ Med Ctr Groningen UMCG, Groningen, Netherlands
[6] Isala Clin, Zwolle, Netherlands
[7] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands
[8] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.333.333
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
333
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
    Jimenez-Zepeda, Victor Hugo
    Dominguez-Martinez, Virginia Jeanet
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (03) : 239 - 244
  • [22] Thalidomide/Dexamethasone Induction Therapy in Newly Diagnosed Myeloma Patients with Renal Failure
    Tosi, P.
    Tacchetti, P.
    Zamagni, E.
    Tacchetti, P.
    Ceccolini, M.
    Perrone, G.
    Brioli, A.
    Pallotti, M. C.
    Petrucci, A.
    Baccarani, M.
    Cavo, M.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S30 - S30
  • [23] Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients
    Gay, Francesca
    Roeloffzen, Wilfried
    Dimopoulos, Meletios A.
    Rosinol, Laura
    van der Klift, Marjolein
    Mina, Roberto
    Oriol Rocafiguera, Albert
    Katodritou, Eirini
    Wu, Ka Lung
    Rodriguez Otero, Paula
    Hajek, Roman
    Antonioli, Elisabetta
    van Duin, Mark
    D'Agostino, Mattia
    Martinez-Lopez, Joaquin
    van Leeuwen-Segarceanu, Elena M.
    Tacchetti, Paola
    van de Donk, Niels W. C. J.
    Weisel, Katja
    Pour, Ludek
    Radocha, Jakub
    Belotti, Angelo
    Schjesvold, Fredrik
    Blade, Joan
    Einsele, Hermann
    Sonneveld, Pieter
    Boccadoro, Mario
    Broijl, Annemiek
    BLOOD, 2023, 142
  • [24] Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
    Wu, Shenghao
    Zheng, Cuiping
    Chen, Songyan
    Cai, Xiaoping
    Shi, Yuejian
    Lin, Bijing
    Chen, Yuemiao
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [25] Quadruplet KCRD (Carfilzomib, Cyclophosphamide, Lenalidomide and Dexamethasone) Induction for Newly Diagnosed Myeloma Patients
    Pawlyn, Charlotte
    Davies, Faith
    Cairns, David
    Striha, Alina
    Hockaday, Anna
    Kishore, Bhuvan
    Garg, Mamta
    Williams, Cathy
    Karunanithi, Kamaraj
    Lindsay, Jindriska
    Jones, John
    Jenner, Matthew
    Russell, Nigel
    Cook, Gordon
    Kaiser, Martin
    Drayson, Mark
    Owen, Roger
    Gregory, Walter
    Morgan, Gareth
    Jackson, Graham
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E2 - E2
  • [26] Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma
    Meletios A Dimopoulos
    Efstathios Kastritis
    Nature Clinical Practice Oncology, 2008, 5 : 690 - 691
  • [27] Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12): : 690 - 691
  • [28] Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
    Korde, Neha
    Roschewski, Mark
    Zingone, Adriana
    Kwok, Mary
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Tageja, Nishant
    Kazandjian, Dickran
    Mailankody, Sham
    Wu, Peter
    Morrison, Candis
    Costello, Rene
    Zhang, Yong
    Burton, Debra
    Mulquin, Marcia
    Zuchlinski, Diamond
    Lamping, Liz
    Carpenter, Ashley
    Wall, Yvonne
    Carter, George
    Cunningham, Schuyler C.
    Gounden, Verena
    Sissung, Tristan M.
    Peer, Cody
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Kong, Katherine A.
    Weng, Li
    Faham, Malek
    Lindenberg, Liza
    Kurdziel, Karen
    Choyke, Peter
    Steinberg, Seth M.
    Figg, William
    Landgren, Ola
    JAMA ONCOLOGY, 2015, 1 (06) : 746 - 754
  • [29] POST-TRANSPLANT CARFILZOMIB (KYPROLIS®), LENALIDOMIDE (REVLIMID®), AND DEXAMETHASONE (KRD) CONSOLIDATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): EFFICACY AND TOLERABILITY OF EXTENDED TREATMENT
    Jakubowiak, A.
    Griffith, K.
    Jasielec, J.
    Rosenbaum, C.
    McDonnell, K.
    Berdeja, J.
    Vij, R.
    Raje, N.
    Reece, D.
    Dytfeld, D.
    Zimmerman, T.
    HAEMATOLOGICA, 2015, 100 : 312 - 312
  • [30] Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients with Newly Diagnosed Multiple Myeloma
    Mikhael, Joseph R.
    Reeder, Craig B.
    Libby, Edward N., III
    Costa, Luciano J.
    Bergsagel, P. Leif
    Buadi, Francis
    Mayo, Angela
    Gano, Katherine
    Wolf, Cassandra
    Dueck, Amylou Constance
    Stewart, A. Keith
    BLOOD, 2012, 120 (21)
12345